Literature DB >> 12068007

Mutations in the helix 3 region of the androgen receptor abrogate ARA70 promotion of 17beta-estradiol-induced androgen receptor transactivation.

Tin Htwe Thin1, Eungseok Kim, Shuyuan Yeh, Erik R Sampson, Yei-Tsung Chen, Loretta L Collins, Ravi Basavappa, Chawnshang Chang.   

Abstract

The influence of estrogen on the development of the male reproductive system may be interrupted in a subset of partial androgen insensitivity syndrome (PAIS) patients. PAIS describes a wide range of male undermasculinization resulting from mutations in the androgen receptor (AR) or steroid metabolism enzymes that perturb androgen-AR regulation of male sex organ development. In this study, we are interested in determining if PAIS-derived AR mutants that respond normally to androgen have altered responses to estrogen in the presence of ARA70, a coregulator previously shown to enhance 17beta-estradiol E2-induced AR transactivation. The wild-type AR (wtAR) and two PAIS AR mutants, AR(S703G) and AR(E709K), all bind to androgen and E2 and subsequently translocate to the nucleus. Whereas ARA70 functionally interacts with the wtAR and the PAIS AR mutants in response to androgen, E2 only promotes the functional interaction between ARA70 and the wtAR but not the PAIS AR mutants. ARA70 increases E2 competitive binding to the wtAR in the presence of low level androgen and also retards E2 dissociation from the wtAR. ARA70 is present in both the cytoplasm and the nucleus of various mouse testicular cells during early embryogenesis day 16, at postpartum day 0 during estradiol synthesis and in the Leydig cells at postpartum day 49. ARA70 may be unable to modulate the PAIS AR mutants-E2 binding, diminishing the effect of E2 via AR during male reproductive system development in patients with such mutations. Therefore, the presence of ARA70 in the testosterone and E2-producing Leydig cells may enhance the overall activity of AR during critical stages of male sex organ development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12068007     DOI: 10.1074/jbc.M202824200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Variable expression of nuclear receptor coactivator 4 (NcoA4) during mouse embryonic development.

Authors:  Alexandra Kollara; Theodore J Brown
Journal:  J Histochem Cytochem       Date:  2010-03-30       Impact factor: 2.479

2.  Cooperative Dynamics of AR and ER Activity in Breast Cancer.

Authors:  Nicholas C D'Amato; Michael A Gordon; Beatrice Babbs; Nicole S Spoelstra; Kiel T Carson Butterfield; Kathleen C Torkko; Vernon T Phan; Valerie N Barton; Thomas J Rogers; Carol A Sartorius; Anthony Elias; Jason Gertz; Britta M Jacobsen; Jennifer K Richer
Journal:  Mol Cancer Res       Date:  2016-08-26       Impact factor: 5.852

3.  Dynamic distribution of nuclear coactivator 4 during mitosis: association with mitotic apparatus and midbodies.

Authors:  Alexandra Kollara; Maurice J Ringuette; Theodore J Brown
Journal:  PLoS One       Date:  2011-07-26       Impact factor: 3.240

4.  Targeting transcriptional coregulator OCA-B/Pou2af1 blocks activated autoreactive T cells in the pancreas and type 1 diabetes.

Authors:  Heejoo Kim; Jelena Perovanovic; Arvind Shakya; Zuolian Shen; Cody N German; Andrea Ibarra; Jillian L Jafek; Nai-Pin Lin; Brian D Evavold; Danny H-C Chou; Peter E Jensen; Xiao He; Dean Tantin
Journal:  J Exp Med       Date:  2021-03-01       Impact factor: 14.307

Review 5.  Expression and function of nuclear receptor co-activator 4: evidence of a potential role independent of co-activator activity.

Authors:  Alexandra Kollara; Theodore J Brown
Journal:  Cell Mol Life Sci       Date:  2012-05-05       Impact factor: 9.261

6.  The interoceptive hippocampus: Mouse brain endocrine receptor expression highlights a dentate gyrus (DG)-cornu ammonis (CA) challenge-sufficiency axis.

Authors:  Richard Lathe; Sheena Singadia; Crispin Jordan; Gernot Riedel
Journal:  PLoS One       Date:  2020-01-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.